Bringing safe and effective therapies to premenopausal women with breast cancer: efforts to broaden eligibility criteria

J. J. Gao; D. Krol; P. Narayan; F. Cardoso; M. M. Regan; M. P. Goetz; S. A. Hurvitz; L. Mauro; C. Hodgdon; C. P. Miller; B. Booth; E. Bloomquist; G. Ison; C. Osgood; V. Bhatnagar; L. Fashoyin-Aje; R. Pazdur; L. Amiri-Kordestani; J. A. Beaver

doi:10.1016/j.annonc.2021.05.356

Bringing safe and effective therapies to premenopausal women with breast cancer: efforts to broaden eligibility criteria

J. J. Gao, D. Krol, P. Narayan, F. Cardoso, M. M. Regan, M. P. Goetz, S. A. Hurvitz, L. Mauro, C. Hodgdon, C. P. Miller, B. Booth, E. Bloomquist, G. Ison, C. Osgood, V. Bhatnagar, L. Fashoyin-Aje, R. Pazdur, L. Amiri-Kordestani, J. A. Beaver

Medical Oncology

Research output: Contribution to journal › Editorial › peer-review

Original language	English (US)
Pages (from-to)	950-953
Number of pages	4
Journal	Annals of Oncology
Volume	32
Issue number	8
DOIs	https://doi.org/10.1016/j.annonc.2021.05.356
State	Published - Aug 2021

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1016/j.annonc.2021.05.356

Cite this

Gao, J. J., Krol, D., Narayan, P., Cardoso, F., Regan, M. M., Goetz, M. P., Hurvitz, S. A., Mauro, L., Hodgdon, C., Miller, C. P., Booth, B., Bloomquist, E., Ison, G., Osgood, C., Bhatnagar, V., Fashoyin-Aje, L., Pazdur, R., Amiri-Kordestani, L., & Beaver, J. A. (2021). Bringing safe and effective therapies to premenopausal women with breast cancer: efforts to broaden eligibility criteria. Annals of Oncology, 32(8), 950-953. https://doi.org/10.1016/j.annonc.2021.05.356

Gao, JJ, Krol, D, Narayan, P, Cardoso, F, Regan, MM, Goetz, MP, Hurvitz, SA, Mauro, L, Hodgdon, C, Miller, CP, Booth, B, Bloomquist, E, Ison, G, Osgood, C, Bhatnagar, V, Fashoyin-Aje, L, Pazdur, R, Amiri-Kordestani, L & Beaver, JA 2021, 'Bringing safe and effective therapies to premenopausal women with breast cancer: efforts to broaden eligibility criteria', Annals of Oncology, vol. 32, no. 8, pp. 950-953. https://doi.org/10.1016/j.annonc.2021.05.356

@article{ba348d435724410e95f11d41f29d1273,

title = "Bringing safe and effective therapies to premenopausal women with breast cancer: efforts to broaden eligibility criteria",

author = "Gao, {J. J.} and D. Krol and P. Narayan and F. Cardoso and Regan, {M. M.} and Goetz, {M. P.} and Hurvitz, {S. A.} and L. Mauro and C. Hodgdon and Miller, {C. P.} and B. Booth and E. Bloomquist and G. Ison and C. Osgood and V. Bhatnagar and L. Fashoyin-Aje and R. Pazdur and L. Amiri-Kordestani and Beaver, {J. A.}",

note = "Funding Information: FC: consulting/advisory for Amgen, Astellas/Medivation, AstraZeneca, Celgene, Daiichi-Sankyo, Eisai, GE Oncology, Genentech, GlaxoSmithKline (GSK), Macrogenics, Medscape, Merck-Sharp, Merus BV, Mylan, Mundipharma, Novartis, Pfizer, Pierre-Fabre, prIME Oncology, Roche, Sanofi, Samsung Bioepis, Seattle Genetics, Teva. MMR: research resources (to institution) for clinical trials from Novartis, Pfizer, Ipsen, TerSera, Merck, Ferring, Pierre Fabre, Roche, AstraZeneca, Bristol-Myers Squibb, Bayer; consulting or advisory role (personal) to Bristol-Myers Squibb, Tolmar Pharmaceuticals; honoraria from WebMD. MPG: reports consulting fees (all to institution) from Eagle Pharmaceuticals, Eli Lilly, Biovica, Novartis, Sermonix, Context Pharm, Pfizer, and Biotheranostics. Research funding from the National Cancer Institute, National Institutes of Health, Department of Defense, Mayo Development, Eli Lilly, Pfizer, Alliance Foundation Trials, Sermonix Pharmaceutical, Translational Breast Cancer Research Consortium, and Minnesota Partnership for Biotechnology and Medical Genomics. SH: contracted research (to institution): Ambrx, Amgen, AstraZeneca, Arvinas, Bayer, Daiichi-Sankyo, Genentech/Roche, Gilead, GSK, Immunomedics, Lilly, Macrogenics, Novartis, Pfizer, OBI Pharma, Pieris, PUMA, Radius, Sanofi, Seattle Genetics, Dignitana, Zymeworks, Phoenix Molecular Designs, Ltd. Travel: Lilly (2019). LM: research resources (to institution) for clinical trials from AstraZeneca, Eli Lilly and Company, Hoffman-La Roche, Pfizer, Radius Pharmaceuticals; consulting or advisory role (personal) to BioTheranostics. CH: Roche/Genentech (honoraria, consulting/advisory), Pfizer (consulting/advisory), Johns Hopkins Hospital (consulting/advisory), NIH/NCI Cancer Moonshot (consulting/advisory), Eli Lilly (travel, accommodations, expenses). All other authors have declared no conflicts of interest. Funding Information: None declared. FC: consulting/advisory for Amgen, Astellas/Medivation, AstraZeneca, Celgene, Daiichi-Sankyo, Eisai, GE Oncology, Genentech, GlaxoSmithKline (GSK), Macrogenics, Medscape, Merck-Sharp, Merus BV, Mylan, Mundipharma, Novartis, Pfizer, Pierre-Fabre, prIME Oncology, Roche, Sanofi, Samsung Bioepis, Seattle Genetics, Teva. MMR: research resources (to institution) for clinical trials from Novartis, Pfizer, Ipsen, TerSera, Merck, Ferring, Pierre Fabre, Roche, AstraZeneca, Bristol-Myers Squibb, Bayer; consulting or advisory role (personal) to Bristol-Myers Squibb, Tolmar Pharmaceuticals; honoraria from WebMD. MPG: reports consulting fees (all to institution) from Eagle Pharmaceuticals, Eli Lilly, Biovica, Novartis, Sermonix, Context Pharm, Pfizer, and Biotheranostics. Research funding from the National Cancer Institute, National Institutes of Health, Department of Defense, Mayo Development, Eli Lilly, Pfizer, Alliance Foundation Trials, Sermonix Pharmaceutical, Translational Breast Cancer Research Consortium, and Minnesota Partnership for Biotechnology and Medical Genomics. SH: contracted research (to institution): Ambrx, Amgen, AstraZeneca, Arvinas, Bayer, Daiichi-Sankyo, Genentech/Roche, Gilead, GSK, Immunomedics, Lilly, Macrogenics, Novartis, Pfizer, OBI Pharma, Pieris, PUMA, Radius, Sanofi, Seattle Genetics, Dignitana, Zymeworks, Phoenix Molecular Designs, Ltd. Travel: Lilly (2019). LM: research resources (to institution) for clinical trials from AstraZeneca, Eli Lilly and Company, Hoffman-La Roche, Pfizer, Radius Pharmaceuticals; consulting or advisory role (personal) to BioTheranostics. CH: Roche/Genentech (honoraria, consulting/advisory), Pfizer (consulting/advisory), Johns Hopkins Hospital (consulting/advisory), NIH/NCI Cancer Moonshot (consulting/advisory), Eli Lilly (travel, accommodations, expenses). All other authors have declared no conflicts of interest.",

year = "2021",

month = aug,

doi = "10.1016/j.annonc.2021.05.356",

language = "English (US)",

volume = "32",

pages = "950--953",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

number = "8",

}

TY - JOUR

T1 - Bringing safe and effective therapies to premenopausal women with breast cancer

T2 - efforts to broaden eligibility criteria

AU - Gao, J. J.

AU - Krol, D.

AU - Narayan, P.

AU - Cardoso, F.

AU - Regan, M. M.

AU - Goetz, M. P.

AU - Hurvitz, S. A.

AU - Mauro, L.

AU - Hodgdon, C.

AU - Miller, C. P.

AU - Booth, B.

AU - Bloomquist, E.

AU - Ison, G.

AU - Osgood, C.

AU - Bhatnagar, V.

AU - Fashoyin-Aje, L.

AU - Pazdur, R.

AU - Amiri-Kordestani, L.

AU - Beaver, J. A.

N1 - Funding Information: FC: consulting/advisory for Amgen, Astellas/Medivation, AstraZeneca, Celgene, Daiichi-Sankyo, Eisai, GE Oncology, Genentech, GlaxoSmithKline (GSK), Macrogenics, Medscape, Merck-Sharp, Merus BV, Mylan, Mundipharma, Novartis, Pfizer, Pierre-Fabre, prIME Oncology, Roche, Sanofi, Samsung Bioepis, Seattle Genetics, Teva. MMR: research resources (to institution) for clinical trials from Novartis, Pfizer, Ipsen, TerSera, Merck, Ferring, Pierre Fabre, Roche, AstraZeneca, Bristol-Myers Squibb, Bayer; consulting or advisory role (personal) to Bristol-Myers Squibb, Tolmar Pharmaceuticals; honoraria from WebMD. MPG: reports consulting fees (all to institution) from Eagle Pharmaceuticals, Eli Lilly, Biovica, Novartis, Sermonix, Context Pharm, Pfizer, and Biotheranostics. Research funding from the National Cancer Institute, National Institutes of Health, Department of Defense, Mayo Development, Eli Lilly, Pfizer, Alliance Foundation Trials, Sermonix Pharmaceutical, Translational Breast Cancer Research Consortium, and Minnesota Partnership for Biotechnology and Medical Genomics. SH: contracted research (to institution): Ambrx, Amgen, AstraZeneca, Arvinas, Bayer, Daiichi-Sankyo, Genentech/Roche, Gilead, GSK, Immunomedics, Lilly, Macrogenics, Novartis, Pfizer, OBI Pharma, Pieris, PUMA, Radius, Sanofi, Seattle Genetics, Dignitana, Zymeworks, Phoenix Molecular Designs, Ltd. Travel: Lilly (2019). LM: research resources (to institution) for clinical trials from AstraZeneca, Eli Lilly and Company, Hoffman-La Roche, Pfizer, Radius Pharmaceuticals; consulting or advisory role (personal) to BioTheranostics. CH: Roche/Genentech (honoraria, consulting/advisory), Pfizer (consulting/advisory), Johns Hopkins Hospital (consulting/advisory), NIH/NCI Cancer Moonshot (consulting/advisory), Eli Lilly (travel, accommodations, expenses). All other authors have declared no conflicts of interest. Funding Information: None declared. FC: consulting/advisory for Amgen, Astellas/Medivation, AstraZeneca, Celgene, Daiichi-Sankyo, Eisai, GE Oncology, Genentech, GlaxoSmithKline (GSK), Macrogenics, Medscape, Merck-Sharp, Merus BV, Mylan, Mundipharma, Novartis, Pfizer, Pierre-Fabre, prIME Oncology, Roche, Sanofi, Samsung Bioepis, Seattle Genetics, Teva. MMR: research resources (to institution) for clinical trials from Novartis, Pfizer, Ipsen, TerSera, Merck, Ferring, Pierre Fabre, Roche, AstraZeneca, Bristol-Myers Squibb, Bayer; consulting or advisory role (personal) to Bristol-Myers Squibb, Tolmar Pharmaceuticals; honoraria from WebMD. MPG: reports consulting fees (all to institution) from Eagle Pharmaceuticals, Eli Lilly, Biovica, Novartis, Sermonix, Context Pharm, Pfizer, and Biotheranostics. Research funding from the National Cancer Institute, National Institutes of Health, Department of Defense, Mayo Development, Eli Lilly, Pfizer, Alliance Foundation Trials, Sermonix Pharmaceutical, Translational Breast Cancer Research Consortium, and Minnesota Partnership for Biotechnology and Medical Genomics. SH: contracted research (to institution): Ambrx, Amgen, AstraZeneca, Arvinas, Bayer, Daiichi-Sankyo, Genentech/Roche, Gilead, GSK, Immunomedics, Lilly, Macrogenics, Novartis, Pfizer, OBI Pharma, Pieris, PUMA, Radius, Sanofi, Seattle Genetics, Dignitana, Zymeworks, Phoenix Molecular Designs, Ltd. Travel: Lilly (2019). LM: research resources (to institution) for clinical trials from AstraZeneca, Eli Lilly and Company, Hoffman-La Roche, Pfizer, Radius Pharmaceuticals; consulting or advisory role (personal) to BioTheranostics. CH: Roche/Genentech (honoraria, consulting/advisory), Pfizer (consulting/advisory), Johns Hopkins Hospital (consulting/advisory), NIH/NCI Cancer Moonshot (consulting/advisory), Eli Lilly (travel, accommodations, expenses). All other authors have declared no conflicts of interest.

PY - 2021/8

Y1 - 2021/8

UR - http://www.scopus.com/inward/record.url?scp=85108191772&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85108191772&partnerID=8YFLogxK

U2 - 10.1016/j.annonc.2021.05.356

DO - 10.1016/j.annonc.2021.05.356

M3 - Editorial

C2 - 33991601

AN - SCOPUS:85108191772

SN - 0923-7534

VL - 32

SP - 950

EP - 953

JO - Annals of Oncology

JF - Annals of Oncology

IS - 8

ER -

Bringing safe and effective therapies to premenopausal women with breast cancer: efforts to broaden eligibility criteria

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this